Combinations of dextromethorphan for the treatment of mood disorders - a review of the evidence

References

• Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder. JAMA. 2003;289(23):3095.
   PubMed Web of Science ®Google Scholar
• Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10:11.
   Google Scholar
• World Health Organization. Depression [Internet]. World Health Organization. Available from: https://www.who.int/news-room/fact-sheets/detail/depression. [cited 2022 Dec 9]
   Google Scholar
• Saltiel PF, Silvershein DI. Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatr Dis Treat. 2015;11(35):875–888.
   PubMedGoogle Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917.
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Salvadore G, Luckenbaugh DA, et al. Rapid onset of antidepressant action. J Clin Psychiatry. 2008;69(6):946–958.
   PubMed Web of Science ®Google Scholar
• Jick H, Jick SS, Kaye JA. Antidepressants and the risk of suicidal behaviors. JAMA. 2004;292(23):2833.
   Google Scholar
• Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856.
   PubMed Web of Science ®Google Scholar
• Henter ID, Park LT, Zarate CA. Novel glutamatergic modulators for the treatment of mood disorders: current status. CNS Drugs. 2021;35(5):527–543.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Smith MA, Pathak S, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 2013;19(9):978–985.
   PubMedGoogle Scholar
• Schwartz J, Murrough JW, Iosifescu DV. Ketamine for treatment-resistant depression: recent developments and clinical applications. Evid Based Ment Health. 2016;19(2)35–38.
   PubMedGoogle Scholar
• Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry. 2004;9(11):984–997.
   PubMed Web of Science ®Google Scholar
• Cooper T, Iosifescu DV. Glutamate alterations in major depressive disorder. In: McIntyre R, Rong C, Subramaniapillai M, et al., editors. Major depressive disorder Elsevier; 2019;161–167.
   Google Scholar
• Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry. 2007;62(11):1310–1316.
   PubMed Web of Science ®Google Scholar
• Lee PH, Perlis RH, Jung JY, et al. Multi-locus genome-wide association analysis supports the role of glutamatergic synaptic transmission in the etiology of major depressive disorder. Transl Psychiatry. 2012;2:e184.
   PubMedGoogle Scholar
• Feyissa AM, Chandran A, Stockmeier CA, et al. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(1):70–75.
   PubMed Web of Science ®Google Scholar
• Murrough JW, Soleimani L, DeWilde KE, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015;45(16):3571–3580.
   PubMed Web of Science ®Google Scholar
• Grunebaum MF, Galfalvy HC, Choo T-H, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry. 2018;175(4):327–335.
   PubMed Web of Science ®Google Scholar
• Commissioner of the FDA approves new nasal spray medication for treatment-resistant depression; available only at a Certified Doctor’s Office or clinic [Internet]. U.S. Food and Drug Administration. FDA. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified. [cited 2022 Dec 5]
   Google Scholar
• McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):383–399.
   PubMed Web of Science ®Google Scholar
• Taylor CP, Traynelis SF, Siffert J, et al. Pharmacology of dextromethorphan: relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. Pharmacol Ther. 2016;164:170–182.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Thomas KL, Lucke-Wold BP, et al. Dextromethorphan: an update on its utility for neurological and neuropsychiatric disorders. Pharmacol Ther. 2016;159:1–22.
   PubMed Web of Science ®Google Scholar
• Romanelli F, Smith KM. Dextromethorphan abuse: clinical effects and management. J Am Pharm Assoc. 2009;49:2.
   Google Scholar
• Schwartz RH. Adolescent abuse of dextromethorphan. Clin Pediatr (Phila). 2005;44(7):565–568.
   PubMed Web of Science ®Google Scholar
• Oh SR, Agrawal S, Sabir S, et al. Dextromethorphan. [ Updated 2022 May 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; [cited 2022 Dec 5]. Available from https://www.ncbi.nlm.nih.gov/books/NBK538216/
   Google Scholar
• Stahl SM. Dextromethorphan/Bupropion: a Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity. CNS Spectr. 2019 Oct;24(5):461–466.
   PubMed Web of Science ®Google Scholar
• Messias E, Everett B. Dextromethorphan and quinidine combination in emotional lability associated with depression: a case report. Prim Care Companion CNS Disord. 2012;14(5):26240.
   Google Scholar
• Lauterbach EC. Treatment resistant depression with loss of antidepressant response: rapid—acting antidepressant action of dextromethorphan, a possible treatment bridging molecule. Psychopharmacol Bull. 2016;46(2):53.
   PubMedGoogle Scholar
• Murrough JW, Stade E, Sayed S, et al. Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: a proof of concept clinical trial. J Affect Disord. 2017;218:277–283.
   PubMed Web of Science ®Google Scholar
• Gant TG. Using deuterium in drug discovery: leaving the label in the drug. J Med Chem. 2013;57(9):3595–3611.
   PubMedGoogle Scholar
• Tabuteau H, Jones A, Anderson A, et al. Effect of AXS-05 (Dextromethorphan-bupropion) in major depressive disorder: a randomized double-blind controlled trial. Am J Psychiatry. 2022;179(7):490–499.
   PubMed Web of Science ®Google Scholar
• Iosifescu DV, Jones A, O’Gorman C, et al. Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder. J Clin Psychiatry. 2022;83:4.
   Google Scholar
• Axsome Therapeutics announces topline results of the STRIDE-1 phase 3 trial in treatment resistant depression and expert call to discuss clinical implications [Internet]. BioSpace. Available from: https://www.biospace.com/article/releases/axsome-therapeutics-announces-topline-results-of-the-stride-1-phase-3-trial-in-treatment-resistant-depression-and-expert-call-to-discuss-clinical-implications/. [cited 2022 Dec 6]
   Google Scholar
• Jones A, Anderson A, Tabuteau H. 40. Efficacy and safety of AXS-05 in the prevention of relapse in patients with treatment-resistant depression: results from the MERIT trial. Poster presented at: Annual Meeting of the American Psychiatric Association; 2022 May 20-24; New Orleans (LA).
   Google Scholar
• O’Gorman C, Jones A, Tabuteau H. W29. Sustained efficacy with long-term treatment with axs-05: results from the comet phase 3 trial, A Long-term, open-label study evaluating the efficacy and safety of axs-05 for the treatment of MDD. Poster presented at: Annual Meeting of the American Society of Clinical Psychopharmacology; 2021, June 1-4; Virtual Conference, USA.
   Google Scholar
• Jones A, Streicher C, Thomas Z, et al. W56. AXS-05 (dextromethorphan-bupropion) improves depressive symptoms and functioning in patients with one prior treatment failure: results from the EVOLVE long-term, open-label study. Poster presented at: Annual Meeting of the American Society of Clinical Psychopharmacology; 2021, June 1-4; Virtual Conference, USA.
   Google Scholar
• Jones A, O’Gorman C, Tabuteau H. T20. Sustained effects of AXS-05, an oral NMDA receptor antagonist, in treatment resistant depression patients: results from the COMET-TRD trial. Poster presented at: American Society of Clinical Psychopharmacology; 2021 June 1- 4; Virtual Conference, USA.
   Google Scholar
• Axsome Therapeutics, Inc. Axsome Therapeutics announces positive efficacy and safety results from phase 3 comet long-term trial and Comet-AU trial of AXS-05 in major depressive disorder [Internet]. GlobeNewswire News Room. Axsome Therapeutics, Inc.; 2020. Available from: https://www.globenewswire.com/en/news-release/2020/12/01/2137234/33090/en/Axsome-Therapeutics-Announces-Positive-Efficacy-and-Safety-Results-from-Phase-3-COMET-Long-Term-Trial-and-COMET-AU-Trial-of-AXS-05-in-Major-Depressive-Disorder.html. [cited 2022 Dec 5]
   Google Scholar
• O’Gorman C, Jones A, Tabuteau H. T19. Rapid reduction in suicidal ideation in patients treated with AXS-05, an oral NMDA receptor antagonist with multimodal activity: results from the COMET-SI trial. Poster presented at: Annual Meeting of the American Society of Clinical Psychopharmacology; 2021, June 1-4; Virtual Conference, USA.
   Google Scholar
• Lee S-Y, Wang T-Y, Chen S-L, et al. Combination of dextromethorphan and Memantine in treating bipolar spectrum disorder: a 12-week double-blind randomized clinical trial. Int J Bipolar Disord. 2020;8:1.
   PubMedGoogle Scholar
• Kelly TF, Lieberman DZ. The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and Bipolar Nos. J Affect Disord. 2014;167:333–335.
   PubMed Web of Science ®Google Scholar
• Lee S-Y, Chen S-L, Chang Y-H, et al. The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder. J Affect Disord. 2012;138(3):295–300.
   PubMed Web of Science ®Google Scholar
• Chen S-L, Lee S-Y, Chang Y-H, et al. Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder. Eur Neuropsychopharmacol. 2014;24(11):1753–1759.
   PubMed Web of Science ®Google Scholar
• Lee S-Y, Chen S-L, Wang T-Y, et al. The COMT VAL158MET polymorphism is associated with response to add-on dextromethorphan treatment in bipolar disorder. J Clin Psychopharmacol. 2017;37(1):94–98.
   PubMed Web of Science ®Google Scholar
• Iosifescu DV. Maintaining the initial clinical response after ketamine in bipolar and unipolar depression: an important next-step challenge. J Clin Psychiatry. 2015;76(6):738–740.
   PubMedGoogle Scholar